Sonja Grill1, Mahdi Fallah2, Robin J Leach3, Ian M Thompson4, Stephen Freedland2, Kari Hemminki5, Donna P Ankerst6. 1. Departments of Life Sciences and Mathematics, Technical University Munich, Munich, Germany. 2. Section of Surgery, Durham Veterans Affairs Hospital and Department of Surgery (Urology) and Pathology, Duke University, Durham, North Carolina. 3. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 4. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 5. Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany; Center for Primary Health Care Research, Lund University, Malmö, Sweden. 6. Departments of Life Sciences and Mathematics, Technical University Munich, Munich, Germany; Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Electronic address: ankerst@uthscsa.edu.
Abstract
PURPOSE: A detailed family history provides an inexpensive alternative to genetic profiling for individual risk assessment. We updated the PCPT Risk Calculator to include detailed family histories. MATERIALS AND METHODS: The study included 55,168 prostate cancer cases and 638,218 controls from the Swedish Family Cancer Database who were 55 years old or older in 1999 and had at least 1 male first-degree relative 40 years old or older and 1 female first-degree relative 30 years old or older. Likelihood ratios, calculated as the ratio of risk of observing a specific family history pattern in a prostate cancer case compared to a control, were used to update the PCPT Risk Calculator. RESULTS: Having at least 1 relative with prostate cancer increased the risk of prostate cancer. The likelihood ratio was 1.63 for 1 first-degree relative 60 years old or older at diagnosis (10.1% of cancer cases vs 6.2% of controls), 2.47 if the relative was younger than 60 years (1.5% vs 0.6%), 3.46 for 2 or more relatives 60 years old or older (1.2% vs 0.3%) and 5.68 for 2 or more relatives younger than 60 years (0.05% vs 0.009%). Among men with no diagnosed first-degree relatives the likelihood ratio was 1.09 for 1 or more second-degree relatives diagnosed with prostate cancer (12.7% vs 11.7%). Additional first-degree relatives with breast cancer, or first-degree or second-degree relatives with prostate cancer compounded these risks. CONCLUSIONS: A detailed family history is an independent predictor of prostate cancer compared to commonly used risk factors. It should be incorporated into decision making for biopsy. Compared with other costly biomarkers it is inexpensive and universally available.
PURPOSE: A detailed family history provides an inexpensive alternative to genetic profiling for individual risk assessment. We updated the PCPT Risk Calculator to include detailed family histories. MATERIALS AND METHODS: The study included 55,168 prostate cancer cases and 638,218 controls from the Swedish Family Cancer Database who were 55 years old or older in 1999 and had at least 1 male first-degree relative 40 years old or older and 1 female first-degree relative 30 years old or older. Likelihood ratios, calculated as the ratio of risk of observing a specific family history pattern in a prostate cancer case compared to a control, were used to update the PCPT Risk Calculator. RESULTS: Having at least 1 relative with prostate cancer increased the risk of prostate cancer. The likelihood ratio was 1.63 for 1 first-degree relative 60 years old or older at diagnosis (10.1% of cancer cases vs 6.2% of controls), 2.47 if the relative was younger than 60 years (1.5% vs 0.6%), 3.46 for 2 or more relatives 60 years old or older (1.2% vs 0.3%) and 5.68 for 2 or more relatives younger than 60 years (0.05% vs 0.009%). Among men with no diagnosed first-degree relatives the likelihood ratio was 1.09 for 1 or more second-degree relatives diagnosed with prostate cancer (12.7% vs 11.7%). Additional first-degree relatives with breast cancer, or first-degree or second-degree relatives with prostate cancer compounded these risks. CONCLUSIONS: A detailed family history is an independent predictor of prostate cancer compared to commonly used risk factors. It should be incorporated into decision making for biopsy. Compared with other costly biomarkers it is inexpensive and universally available.
Authors: Sholom Wacholder; Patricia Hartge; Ross Prentice; Montserrat Garcia-Closas; Heather Spencer Feigelson; W Ryan Diver; Michael J Thun; David G Cox; Susan E Hankinson; Peter Kraft; Bernard Rosner; Christine D Berg; Louise A Brinton; Jolanta Lissowska; Mark E Sherman; Rowan Chlebowski; Charles Kooperberg; Rebecca D Jackson; Dennis W Buckman; Peter Hui; Ruth Pfeiffer; Kevin B Jacobs; Gilles D Thomas; Robert N Hoover; Mitchell H Gail; Stephen J Chanock; David J Hunter Journal: N Engl J Med Date: 2010-03-18 Impact factor: 91.245
Authors: Donna P Ankerst; Josef Hoefler; Sebastian Bock; Phyllis J Goodman; Andrew Vickers; Javier Hernandez; Lori J Sokoll; Martin G Sanda; John T Wei; Robin J Leach; Ian M Thompson Journal: Urology Date: 2014-06 Impact factor: 2.649
Authors: Robert K Nam; Michael W Kattan; Joseph L Chin; John Trachtenberg; Rajiv Singal; Ricardo Rendon; Laurence H Klotz; Linda Sugar; Christopher Sherman; Jonathan Izawa; David Bell; Aleksandra Stanimirovic; Vasundara Venkateswaran; Eleftherios P Diamandis; Changhong Yu; D Andrew Loblaw; Steven A Narod Journal: J Clin Oncol Date: 2011-06-20 Impact factor: 44.544
Authors: Greg Trottier; Monique J Roobol; Nathan Lawrentschuk; Peter J Boström; Kimberly A Fernandes; Antonio Finelli; Karen Chadwick; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Alexandre R Zlotta; Neil E Fleshner Journal: BJU Int Date: 2011-04-20 Impact factor: 5.588
Authors: Dipen J Parekh; Donna Pauler Ankerst; Betsy A Higgins; Javier Hernandez; Edith Canby-Hagino; Timothy Brand; Dean A Troyer; Robin J Leach; Ian M Thompson Journal: Urology Date: 2006-12 Impact factor: 2.649
Authors: Donna Pauler Ankerst; Jack Groskopf; John R Day; Amy Blase; Harry Rittenhouse; Brad H Pollock; Cathy Tangen; Dipen Parekh; Robin J Leach; Ian Thompson Journal: J Urol Date: 2008-08-15 Impact factor: 7.450
Authors: Donna P Ankerst; Martin Goros; Scott A Tomlins; Dattatraya Patil; Ziding Feng; John T Wei; Martin G Sanda; Jonathan Gelfond; Ian M Thompson; Robin J Leach; Michael A Liss Journal: Eur Urol Focus Date: 2018-02-13
Authors: Elena S Kotova; Yulia A Savochkina; Yuriy V Doludin; Alexander O Vasilyev; Elena A Prilepskay; Natalia V Potoldykova; Konstantin A Babalyan; Alexandra V Kanygina; Andrey O Morozov; Alexander V Govorov; Dmitry V Enikeev; Elena S Kostryukova; Elena N Ilina; Vadim M Govorun; Dmitry Y Pushkar; Elena I Sharova Journal: Res Rep Urol Date: 2020-09-17
Authors: Matthew B Clements; Emily A Vertosick; Lourdes Guerrios-Rivera; Amanda M De Hoedt; Javier Hernandez; Michael A Liss; Robin J Leach; Stephen J Freedland; Alexander Haese; Francesco Montorsi; Stephen A Boorjian; Cedric Poyet; Donna P Ankerst; Andrew J Vickers Journal: Eur Urol Date: 2021-12-31 Impact factor: 24.267
Authors: Mark Thalgott; Martina Kron; Johannes M Brath; Donna P Ankerst; Ian M Thompson; Juergen E Gschwend; Kathleen Herkommer Journal: World J Urol Date: 2017-11-21 Impact factor: 4.226
Authors: Lauren Barber; Travis Gerke; Sarah C Markt; Samuel F Peisch; Kathryn M Wilson; Thomas Ahearn; Edward Giovannucci; Giovanni Parmigiani; Lorelei A Mucci Journal: Clin Cancer Res Date: 2018-08-06 Impact factor: 12.531
Authors: Amirhossein Jalali; Robert W Foley; Robert M Maweni; Keefe Murphy; Dara J Lundon; Thomas Lynch; Richard Power; Frank O'Brien; Kieran J O'Malley; David J Galvin; Garrett C Durkan; T Brendan Murphy; R William Watson Journal: BMC Med Inform Decis Mak Date: 2020-07-03 Impact factor: 2.796
Authors: Enrique Gomez Gomez; Juan José Salamanca Bustos; Julia Carrasco Valiente; Jose Luis Fernandez Rueda; Ana Blanca; José Valero Rosa; Ines Bravo Arrebola; Javier Marquez López; Juan Manuel Jimenez Vacas; Raul Luque; Maria José Requena Tapia Journal: BMJ Open Date: 2019-11-12 Impact factor: 2.692